The neutralization of CCL22 using a specific antibody has been shown to reverse these pro-tumorigenic effects, suggesting a therapeutic approach to mitigating cancer progression by targeting CCL22 (Zhang Y. et al., 2023). Here, CCL22 is linked to cancer.